High prevalence of hepatitis delta virus among people with hepatitis B virus and HIV coinfection in Botswana.
Humans
Hepatitis B virus
Hepatitis B Surface Antigens
Hepatitis Delta Virus
/ genetics
Hepatitis B, Chronic
/ complications
Hepatitis B
/ epidemiology
Retrospective Studies
Hepatitis B e Antigens
Prevalence
Botswana
/ epidemiology
Cross-Sectional Studies
HIV Infections
/ complications
Hepatitis B Antibodies
RNA
Immunoglobulin M
Coinfection
/ epidemiology
Botswana
Hepatitis delta virus
People with HIV
Prevalence
Journal
Journal of infection and public health
ISSN: 1876-035X
Titre abrégé: J Infect Public Health
Pays: England
ID NLM: 101487384
Informations de publication
Date de publication:
Nov 2023
Nov 2023
Historique:
received:
22
05
2023
revised:
12
06
2023
accepted:
15
08
2023
medline:
2
11
2023
pubmed:
21
9
2023
entrez:
21
9
2023
Statut:
ppublish
Résumé
Approximately 15-20 million people worldwide are infected with hepatitis delta virus (HDV), which is approximately 5 % of people with chronic hepatitis B virus (HBV). Sub-Saharan Africa has high HDV prevalence, leading to worse clinical outcomes among people who are HIV/HBV/HDV tri-infected. There are limited data on HDV prevalence among people with HIV (PWH) who are HBV-infected and uninfected in Botswana. We, therefore, determined HDV prevalence among PWH in Botswana. This was a retrospective cross-sectional study utilizing archived plasma samples from PWH with results for HBV markers such as hepatitis B surface antigen (HBsAg), hepatitis B core antibody (anti-HBc), immunoglobulin M antibody to hepatitis B core antigen (IgM anti-HBc) and hepatitis B e antigen (HBeAg). Samples were categorized according to their HBsAg status and screened for anti-HDV antibodies. Total nucleic acid was extracted from samples with a single positive anti-HDV result, and HDV ribonucleic acid (RNA) load was quantified using the Altona Diagnostic RealStar® HDV RT-PCR kit. Statistical analysis was performed using STATA version 14.0 where p-values < 0.05 were considered statistically significant. The study cohort (n = 478) included both HBsAg positive (44 %) and negative (56 %) participants, with a median age of 42 [IQR; 41-43]. Anti-HDV prevalence of (15/211) [7.1 %, 95 % CI: 4.4 - 11.4] was recorded among HBsAg positive participants, all of whom were IgM anti-HBc negative, while 5/6 participants were HBeAg negative. HDV RNA load was detected in 11/12 (92 %) anti-HDV-positive participants. No HDV prevalence was recorded among participants who were HBsAg negative, therefore, the overall HDV prevalence was (15/478) [3.1 %, 95 % CI: 1.9 - 5.1]. HIV viral load suppression was statistically insignificant, irrespective of HDV status. We report high HDV prevalence among HBsAg-positive PWH in Botswana. Most HDV-positive participants had active HDV infection, therefore, we recommend HDV screening in this cohort to guide their clinical care.
Sections du résumé
BACKGROUND
BACKGROUND
Approximately 15-20 million people worldwide are infected with hepatitis delta virus (HDV), which is approximately 5 % of people with chronic hepatitis B virus (HBV). Sub-Saharan Africa has high HDV prevalence, leading to worse clinical outcomes among people who are HIV/HBV/HDV tri-infected. There are limited data on HDV prevalence among people with HIV (PWH) who are HBV-infected and uninfected in Botswana. We, therefore, determined HDV prevalence among PWH in Botswana.
METHODS
METHODS
This was a retrospective cross-sectional study utilizing archived plasma samples from PWH with results for HBV markers such as hepatitis B surface antigen (HBsAg), hepatitis B core antibody (anti-HBc), immunoglobulin M antibody to hepatitis B core antigen (IgM anti-HBc) and hepatitis B e antigen (HBeAg). Samples were categorized according to their HBsAg status and screened for anti-HDV antibodies. Total nucleic acid was extracted from samples with a single positive anti-HDV result, and HDV ribonucleic acid (RNA) load was quantified using the Altona Diagnostic RealStar® HDV RT-PCR kit. Statistical analysis was performed using STATA version 14.0 where p-values < 0.05 were considered statistically significant.
RESULTS
RESULTS
The study cohort (n = 478) included both HBsAg positive (44 %) and negative (56 %) participants, with a median age of 42 [IQR; 41-43]. Anti-HDV prevalence of (15/211) [7.1 %, 95 % CI: 4.4 - 11.4] was recorded among HBsAg positive participants, all of whom were IgM anti-HBc negative, while 5/6 participants were HBeAg negative. HDV RNA load was detected in 11/12 (92 %) anti-HDV-positive participants. No HDV prevalence was recorded among participants who were HBsAg negative, therefore, the overall HDV prevalence was (15/478) [3.1 %, 95 % CI: 1.9 - 5.1]. HIV viral load suppression was statistically insignificant, irrespective of HDV status.
CONCLUSIONS
CONCLUSIONS
We report high HDV prevalence among HBsAg-positive PWH in Botswana. Most HDV-positive participants had active HDV infection, therefore, we recommend HDV screening in this cohort to guide their clinical care.
Identifiants
pubmed: 37734129
pii: S1876-0341(23)00278-2
doi: 10.1016/j.jiph.2023.08.011
pmc: PMC10589822
pii:
doi:
Substances chimiques
Hepatitis B Surface Antigens
0
Hepatitis B e Antigens
0
Hepatitis B Antibodies
0
RNA
63231-63-0
Immunoglobulin M
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1736-1741Informations de copyright
Copyright © 2023 The Author(s). Published by Elsevier Ltd.. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest We have no conflict of interest to declare.
Références
Open Forum Infect Dis. 2023 Jan 06;10(1):ofac707
pubmed: 36686633
Hepatology. 2021 Feb;73(2):861-864
pubmed: 32628280
Nat Commun. 2019 May 8;10(1):2098
pubmed: 31068585
Trans R Soc Trop Med Hyg. 1989 Jan-Feb;83(1):110-6
pubmed: 2513670
J Clin Med. 2020 Jan 14;9(1):
pubmed: 31947588
Viruses. 2021 Apr 28;13(5):
pubmed: 33924806
Am J Trop Med Hyg. 2011 Aug;85(2):390-4
pubmed: 21813864
J Infect Dis. 2020 Apr 27;221(10):1677-1687
pubmed: 31778167
Hepatology. 2012 Mar;55(3):685-94
pubmed: 22031488
BMC Infect Dis. 2015 Aug 13;15:335
pubmed: 26268355
Clin Infect Dis. 2014 Jun;58(11):1549-53
pubmed: 24633686
AIDS. 2013 Jan 14;27(2):191-201
pubmed: 23032418
AIDS Res Hum Retroviruses. 2013 Dec;29(12):1535-40
pubmed: 23972039
PLoS One. 2014 Jun 10;9(6):e99971
pubmed: 24915064
J Hepatol. 2010 May;52(5):658-64
pubmed: 20346531
PLoS One. 2015 Jul 28;10(7):e0134037
pubmed: 26218239
Virol J. 2010 Oct 26;7:283
pubmed: 20977704
Clin Infect Dis. 2006 Dec 15;43(12):1612-5
pubmed: 17109297
J Hepatol. 2017 Feb;66(2):297-303
pubmed: 27746337
J Hepatol. 2020 Sep;73(3):523-532
pubmed: 32335166
Lancet HIV. 2020 Jun;7(6):e422-e433
pubmed: 32504575
Sci Rep. 2018 Aug 2;8(1):11617
pubmed: 30072752
Arch Public Health. 2021 Oct 19;79(1):180
pubmed: 34663473